Form 8-K - Current report:
SEC Accession No. 0001193125-21-151781
Filing Date
2021-05-05
Accepted
2021-05-05 16:31:16
Documents
14
Period of Report
2021-05-03
Items
Item 5.04: Temporary Suspension of Trading Under Registrant's Employee Benefit Plans
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d915811d8k.htm   iXBRL 8-K 33529
2 EX-99.1 d915811dex991.htm EX-99.1 4063
  Complete submission text file 0001193125-21-151781.txt   218828

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrk-20210503.xsd EX-101.SCH 5137
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20210503_def.xml EX-101.DEF 14802
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20210503_lab.xml EX-101.LAB 24956
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20210503_pre.xml EX-101.PRE 15965
7 EXTRACTED XBRL INSTANCE DOCUMENT d915811d8k_htm.xml XML 9460
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 21893882
SIC: 2834 Pharmaceutical Preparations